107.115 USD
+4.93 (+4.83%)
BNTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. Both the profitability and the financial health of BNTX get a neutral evaluation. Nothing too spectacular is happening here. BNTX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BNTX had negative earnings in the past year.
In the past year BNTX has reported a negative cash flow from operations.
Of the past 5 years BNTX 4 years were profitable.
Of the past 5 years BNTX 4 years had a positive operating cash flow.
1.2 Ratios
BNTX's Return On Assets of -2.68% is amongst the best of the industry. BNTX outperforms 87.12% of its industry peers.
BNTX has a better Return On Equity (-3.09%) than 89.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| ROIC | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of BNTX (85.62%) is better than 88.26% of its industry peers.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
BNTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
2. Health
2.1 Basic Checks
BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNTX has been increased compared to 1 year ago.
BNTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BNTX has a worse debt to assets ratio.
2.2 Solvency
BNTX has an Altman-Z score of 6.38. This indicates that BNTX is financially healthy and has little risk of bankruptcy at the moment.
BNTX has a better Altman-Z score (6.38) than 76.70% of its industry peers.
BNTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BNTX (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.38 |
ROIC/WACCN/A
WACC7.27%
2.3 Liquidity
BNTX has a Current Ratio of 7.12. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.12, BNTX is doing good in the industry, outperforming 70.64% of the companies in the same industry.
A Quick Ratio of 7.02 indicates that BNTX has no problem at all paying its short term obligations.
The Quick ratio of BNTX (7.02) is better than 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.12 | ||
| Quick Ratio | 7.02 |
3. Growth
3.1 Past
The earnings per share for BNTX have decreased strongly by -20.92% in the last year.
The Revenue has been growing slightly by 3.70% in the past year.
The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
3.2 Future
Based on estimates for the next years, BNTX will show a small growth in Earnings Per Share. The EPS will grow by 7.38% on average per year.
BNTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.25% yearly.
EPS Next Y-18.79%
EPS Next 2Y-8.96%
EPS Next 3Y-5.74%
EPS Next 5Y7.38%
Revenue Next Year3.96%
Revenue Next 2Y0.72%
Revenue Next 3Y1.18%
Revenue Next 5Y2.25%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as BNTX's earnings are expected to decrease with -5.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.96%
EPS Next 3Y-5.74%
5. Dividend
5.1 Amount
No dividends for BNTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BNTX (1/13/2026, 3:56:05 PM)
107.115
+4.93 (+4.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.81%
Inst Owner Change0.66%
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap25.76B
Revenue(TTM)3.15B
Net Income(TTM)-571.60M
Analysts81.48
Price Target139.41 (30.15%)
Short Float %6.17%
Short Ratio5.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.13%
Min EPS beat(2)21.85%
Max EPS beat(2)44.42%
EPS beat(4)4
Avg EPS beat(4)77.6%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)44.65%
EPS beat(12)9
Avg EPS beat(12)207.14%
EPS beat(16)12
Avg EPS beat(16)164.98%
Revenue beat(2)2
Avg Revenue beat(2)63.4%
Min Revenue beat(2)55.06%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)33.69%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)5
Avg Revenue beat(8)18.96%
Revenue beat(12)6
Avg Revenue beat(12)5.54%
Revenue beat(16)9
Avg Revenue beat(16)12.1%
PT rev (1m)-0.21%
PT rev (3m)0.1%
EPS NQ rev (1m)80.22%
EPS NQ rev (3m)97.75%
EPS NY rev (1m)-1.55%
EPS NY rev (3m)33.34%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-15.37%
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)27.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.99 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.19 | ||
| P/tB | 1.32 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.77
EYN/A
EPS(NY)-3.86
Fwd EYN/A
FCF(TTM)-5.32
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS15.33
BVpS89.84
TBVpS81.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.62% | ||
| FCFM | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 202.92% | ||
| Cap/Sales | 24.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.12 | ||
| Quick Ratio | 7.02 | ||
| Altman-Z | 6.38 |
F-Score3
WACC7.27%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
EPS Next Y-18.79%
EPS Next 2Y-8.96%
EPS Next 3Y-5.74%
EPS Next 5Y7.38%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
Revenue Next Year3.96%
Revenue Next 2Y0.72%
Revenue Next 3Y1.18%
Revenue Next 5Y2.25%
EBIT growth 1Y-6.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.38%
EBIT Next 3Y13.64%
EBIT Next 5Y19.73%
FCF growth 1Y-123.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.92%
OCF growth 3Y-38.43%
OCF growth 5YN/A
BIONTECH SE-ADR / BNTX FAQ
Can you provide the ChartMill fundamental rating for BIONTECH SE-ADR?
ChartMill assigns a fundamental rating of 3 / 10 to BNTX.
What is the valuation status of BIONTECH SE-ADR (BNTX) stock?
ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (BNTX). This can be considered as Overvalued.
How profitable is BIONTECH SE-ADR (BNTX) stock?
BIONTECH SE-ADR (BNTX) has a profitability rating of 4 / 10.
What is the expected EPS growth for BIONTECH SE-ADR (BNTX) stock?
The Earnings per Share (EPS) of BIONTECH SE-ADR (BNTX) is expected to decline by -18.79% in the next year.
How sustainable is the dividend of BIONTECH SE-ADR (BNTX) stock?
The dividend rating of BIONTECH SE-ADR (BNTX) is 0 / 10 and the dividend payout ratio is 0%.